An observational study in Cluneal Syndrome, sponsored by Gaziosmanpasa Research and Education Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Gaziosmanpasa Research and Education Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Neuralgia with a site in Turkey — 29 open to participants now, 30 under way, none of them phase 3. Neuralgia · Turkey.
Among the 79 studies in Neuralgia with a site in Turkey, this one is the 32nd largest by enrollment of the 43 observational ones that give a count, is one of 13 that started in 2025, is one of 43 observational ones, and was the 56th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →29 of the 79 studies in Neuralgia with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 18+
Istanbul Physical Medicine Rehabilitation Training and Research Hospital · Sites in Turkey
Ages 18–65
Kutahya Health Sciences University · Sites in Turkey
Ages 18+
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Sites in Turkey
Ages 18–65
Marmara University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 102 across 232 observational studies indexed under Neuralgia.
Median enrollment 60 across the 36 interventional studies, 96 across the 43 observational. Of the 42 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 79 has an industry lead sponsor. The 10 most frequent:
Gaziosmanpasa Research and Education Hospital is the lead sponsor of 128 studies on the registry; 27 are open to participants now.
Gaziosmanpasa Research and Education Hospital has 2 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuralgia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846410Istanbul Physical Medicine Rehabilitation Training and Research HospitalVirtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury | 2026-11 |
| NCT07844772Istanbul Training and Research HospitalSerum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis | 2026-12 |
| NCT06430918Bozyaka Training and Research HospitalNeuropathic Pain and it's Relation to Sleep Quality in Knee Osteoarthritis | 2026-12-01 |
| NCT07550348Ataturk UniversityBupivacaine-Lidocaine vs Bupivacaine for Ultrasound-Guided Popliteal Sciatic Nerve Block | 2026-12-01 |
| NCT07596823Ankara City Hospital BilkentHematological Indices and Sympathetic Block Response in Neuropathic Pain | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 79 studies in Neuralgia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Superior cluneal nerve (SCN) entrapment is an underdiagnosed cause of chronic low back and gluteal pain. Although diagnostic nerve block is considered the gold standard for confirming SCN entrapment, there is no consensus regarding the optimal injection approach. This prospective observational study aims to compare the clinical effectiveness of proximal and distal ultrasound-guided SCN block techniques in patients diagnosed with SCN entrapment. Pain intensity and functional outcomes will be evaluated over the follow-up period to assess differences between the two approaches.
The primary objective of this study is to compare the effects of two different ultrasound-guided injection techniques on pain intensity, functional status, neuropathic pain components, and quality of life in patients with suspected superior cluneal nerve (SCN) entrapment. Pain severity will be assessed using the Visual Analog Scale (VAS), functional status using the Oswestry Disability Index (ODI), neuropathic pain components using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), and quality of life using the Short Form-12 (SF-12). The study aims to determine which injection technique provides superior clinical outcomes.
The secondary objective is to evaluate lumbosacral angle, lumbar lordosis angle, pelvic tilt, sacral tilt, and the presence of scoliosis, and to investigate the relationship between these postural and radiological parameters, SCN entrapment, and treatment response.
Through this study, ultrasound-guided injection techniques used in the diagnosis and treatment of SCN entrapment will be comparatively evaluated, addressing an important gap in the current literature and providing high-level scientific evidence to guide clinicians in the management of chronic low back and gluteal pain.
This study is designed as a prospective, assessor-blinded observational study comparing two different ultrasound-guided injection techniques in patients with superior cluneal nerve entrapment confirmed by diagnostic nerve block. The study population will consist of patients presenting to the Algology Outpatient Clinic of Health Sciences University Gaziosmanpaşa Physical Medicine and Rehabilitation Training and Research Hospital during the study period, who meet the inclusion and exclusion criteria, have chronic low back and/or gluteal pain, are suspected of having SCN entrapment based on clinical examination, have not benefited from conservative treatment, and voluntarily agree to participate in the study.
Based on a power analysis with 95% power, a total of 54 patients are planned to be included in the study, with 27 patients allocated to each group.
The study population will consist of adult patients aged 18 to 75 years presenting with chronic low back and/or gluteal pain lasting longer than three months, who are clinically suspected of having superior cluneal nerve entrapment based on physical examination findings. Eligible participants will be those who have not responded to conservative treatment and who attend the Algology Outpatient Clinic during the study period. Only patients with unilateral symptoms who meet all inclusion and exclusion criteria and who provide written informed consent will be included in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ultrasound-guided proximal interfascial (plane block) approach for suspected superior cluneal nerve entrapment.
Procedure: Ultrasound-guided proximal superior cluneal nerve injection
Ultrasound-guided distal perineural approach for suspected superior cluneal nerve entrapment.
Procedure: Ultrasound-guided distal superior cluneal nerve injection
The ultrasound probe will be placed over the posterior superior iliac crest to visualize the fibro-osseous tunnel where the superior cluneal nerve passes. Using an in-plane approach, the needle will be advanced toward the target area, and the injection will be administered at the fascial exit point of the nerve. A total injectate volume of 5 cc (2 cc bupivacaine, 2 cc dexamethasone, and 1 cc normal saline) will be administered. All procedures will be performed in the prone position under standard aseptic conditions.
Patients randomized to the proximal injection group will undergo ultrasound-guided injection above the iliac crest level. The target will be the plane beneath the posterior layer of the thoracolumbar fascia. Using an in-plane approach, the injectate will be delivered into the interfascial plane. A total injectate volume of 5 cc (2 cc bupivacaine, 2 cc dexamethasone, and 1 cc normal saline) will be administered under ultrasound guidance. Patient positioning and aseptic conditions will be identical to those used in the distal perineural injection group.
Visual Analog Scale (VAS)
Primary Outcome Measure Visual Analog Scale for Pain (VAS): Change in pain intensity assessed using the Visual Analog Scale (VAS).The VAS is a 10-cm horizontal scale ranging from 0 (no pain) to 10 (worst imaginable pain).Higher scores indicate greater pain intensity, and a reduction in VAS score represents clinical improvement.
Time frame: Baseline, 1 month, and 3 months
Oswestry Disability Index (ODI)
Oswestry Disability Index (ODI): Change in disability related to low back pain assessed using the Oswestry Disability Index (ODI).The validated and reliability-tested Turkish version of the ODI will be used in this study.The ODI consists of 10 items, each scored from 0 to 5, yielding a maximum total raw score of 50.The total score is converted to a percentage using the following formula:ODI percentage = (Total score / 50) × 100 Higher percentage scores indicate greater disability. Disability levels are interpreted as follows: * 0-20%: Minimal disability * 21-40%: Moderate disability * 41-60%: Severe disability * 61-80%: Crippling disability * 81-100%: Bed-bound or exaggerated symptoms A decrease in ODI percentage score indicates improvement in functional status.
Time frame: Baseline, 1 month, and 3 months
Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
Assessment of neuropathic pain features using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaire.The LANSS scale consists of 7 items with a total score ranging from 0 to 24.A score of ≥12 indicates the presence of neuropathic pain mechanisms.Higher scores reflect greater neuropathic pain components.
Time frame: Baseline, 1 month, and 3 months
Short Form-12 Health Survey (SF-12)
Health-related quality of life assessed using the Short Form-12 Health Survey (SF-12).The SF-12 generates two composite scores: * Physical Component Summary (PCS) * Mental Component Summary (MCS) Both PCS and MCS scores are calculated according to standard scoring algorithms.Higher scores indicate better physical and mental health-related quality of life, respectively.In this study, PCS and MCS scores will be analyzed separately to evaluate physical and mental aspects of quality of life.
Time frame: Baseline, 1 month, and 3 months
Baseline Postural and Radiological Characteristics in Patients with Superior Cluneal Nerve Entrapment
Baseline postural and radiological characteristics will be assessed prior to intervention in patients with superior cluneal nerve entrapment. Previously obtained standing lateral lumbosacral and pelvic radiographs will be used. Lumbar lordosis, sacral slope, lumbosacral angle, and pelvic tilt will be measured as radiographic angles in degrees on standing lateral images and categorized as decreased/normal/increased (lumbar lordosis, sacral slope, lumbosacral angle) or anterior/normal/posterior (pelvic tilt). Scoliosis will be evaluated based on physical examination and review of existing radiographs and MRI scans; when clinically indicated, standing scoliosis radiographs will be obtained. Scoliosis will be assessed using the Cobb method and recorded as present or absent. These findings will be descriptively reported.
Time frame: Baseline (pre-intervention)
Plan to share: No — Individual participant data will not be shared due to institutional data protection policies and the absence of participant consent for data sharing beyond the scope of the current study.
Ran from Dec 2025 to primary completion in Jul 2026, 7 months.
Of 77 non-industry observational studies under Neuralgia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 7 months is below that.
Counting every sponsor, half of 88 studies reached it within 18 months; a quarter within 12 and three quarters within 55.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jul 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gaziosmanpasa Research and Education Hospital →